Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
Santosh Karnewar, Vaishnavi Karnewar, Laura S. Shankman, Gary K. Owens
Santosh Karnewar, Vaishnavi Karnewar, Laura S. Shankman, Gary K. Owens
View: Text | PDF
Research Article Vascular biology

Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality

  • Text
  • PDF
Abstract

The use of senolytic agents to remove senescent cells from atherosclerotic lesions is controversial. A common limitation of previous studies is the failure to rigorously define the effects of senolytic agent ABT-263 (Navitoclax) on smooth muscle cells (SMC) despite studies claiming that these cells are the major source of senescent cells. Moreover, there are no studies on the effect of ABT-263 on endothelial cells (EC), which — along with SMC — comprise 90% of α-smooth muscle actin+ (α-SMA+) myofibroblast-like cells in the protective fibrous cap. Here we tested the hypothesis that treatment of advanced atherosclerotic mice with ABT-263 will reduce lesion size and increase plaque stability. SMC (Myh11-CreERT2-eYFP) and EC (Cdh5-CreERT2-eYFP) lineage tracing Apoe–/– mice were fed a western diet (WD) for 18 weeks, followed by ABT-263 at 100 mg/kg/bw for 6 weeks or 50 mg/kg/bw for 9 weeks. ABT-263 treatment did not change lesion size or lumen area of the brachiocephalic artery (BCA). However, ABT-263 treatment reduced SMC by 90% and increased EC contributions to lesions via EC-to-mesenchymal transition (EndoMT) by 60%. ABT-263 treatment also reduced α-SMA+ fibrous cap thickness by 60% and was associated with a > 50% mortality rate. Taken together, ABT-263 treatment of WD-fed Apoe–/– mice with advanced lesions resulted in multiple detrimental changes, including reduced indices of stability and increased mortality.

Authors

Santosh Karnewar, Vaishnavi Karnewar, Laura S. Shankman, Gary K. Owens

×

Figure 8

Treatment of Apoe–/– mice with advanced lesions with a reduced dose (50mg/kg/bw) of ABT-263 decreased collagen content within BCA lesions and was also associated with increased mortality.

Options: View larger image (or click on image) Download as PowerPoint
Treatment of Apoe–/– mice with advanced lesions with a reduced dose (50m...
(A) Experimental design. EC lineage tracing Apoe–/– mice were fed a WD for 18 weeks followed by 50 mg/kg/bw ABT-263 treatment on WD for 9 weeks. (B) Probability of survival (Kaplan-Meier curve). (C) Representative 10× images of MOVAT staining of the BCA. Scale bar: 100 μm. (D) Lesion area from C. (E) Lumen area from C. (F) External elastic lamina (EEL) area from C, for outward remodeling. (G) Necrotic core area normalized to lesion size. (H) Representative 10× images of Picrosirius red staining on BCA. Scale bar: 100 μm. (I) Quantification of mature (red) collagen content normalized to lesion area from H. (J) Representative confocal images of costaining for eYFP (for detecting EC), α-SMA+, and DAPI in advanced BCA lesions. Scale bars: 100 μm. (K) α-SMA+ cap area normalized to lesion area (α-SMA+ cap area/lesion area). (L) Quantification of the percentage α-SMA+ (α-SMA+/DAPI) cells in the fibrous cap. (M) Quantification of the percentage EC-derived (Cdh5-eYFP+/DAPI+) cells in the lesion. (N) Quantification of the percentage EC-derived α-SMA+ (Cdh5-eYFP+ α-SMA+/α-SMA+) cells in lesions. The 2-way ANOVA method was used for statistical analysis in D, G, and K–L, and biologically independent animals are indicated as individual dots. Data are shown as mean ± SEM. A Mantel-Cox test was used for statistical analysis in B. The P values are indicated on the respective graphs.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts